Cargando…
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
Despite comprehensive genomic analyses, no targeted therapies are approved for bladder cancer. Here, we investigate whether a single and combination therapy with targeted agents exert antitumor effects on bladder cancer cells through genomic alterations using a three-dimensional (3D) high-throughput...
Autores principales: | Kim, Hyera, Lee, Su Jin, Lee, In Kyoung, Min, Suejean C., Sung, Hyun Hwan, Jeong, Byong Chang, Lee, Jeeyun, Park, Se Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215775/ https://www.ncbi.nlm.nih.gov/pubmed/32325639 http://dx.doi.org/10.3390/ijms21082825 |
Ejemplares similares
-
PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015) -
NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
por: MOON, DU G., et al.
Publicado: (2014) -
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012) -
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
por: Kim, Hee Kyung, et al.
Publicado: (2016) -
The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)